vs
EXACT SCIENCES CORP（EXAS）与Mativ Holdings, Inc.（MATV）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Mativ Holdings, Inc.的1.9倍（$878.4M vs $463.1M），Mativ Holdings, Inc.净利率更高（21.8% vs -9.8%，领先31.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 1.0%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $8.0M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -3.8%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
EXAS vs MATV — 直观对比
营收规模更大
EXAS
是对方的1.9倍
$463.1M
营收增速更快
EXAS
高出22.1%
1.0%
净利率更高
MATV
高出31.6%
-9.8%
自由现金流更多
EXAS
多$112.4M
$8.0M
两年增速更快
EXAS
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $463.1M |
| 净利润 | $-86.0M | $100.8M |
| 毛利率 | 70.1% | 18.8% |
| 营业利润率 | -9.4% | 2.2% |
| 净利率 | -9.8% | 21.8% |
| 营收同比 | 23.1% | 1.0% |
| 净利润同比 | 90.1% | 6620.0% |
| 每股收益（稀释后） | $-0.45 | $1.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASMATV
| Q4 25 | $878.4M | $463.1M | ||
| Q3 25 | $850.7M | $513.7M | ||
| Q2 25 | $811.1M | $525.4M | ||
| Q1 25 | $706.8M | $484.8M | ||
| Q4 24 | $713.4M | $458.6M | ||
| Q3 24 | $708.7M | $498.5M | ||
| Q2 24 | $699.3M | $523.8M | ||
| Q1 24 | $637.5M | $500.2M |
净利润EXASMATV
| Q4 25 | $-86.0M | $100.8M | ||
| Q3 25 | $-19.6M | $-3.2M | ||
| Q2 25 | $-1.2M | $-9.5M | ||
| Q1 25 | $-101.2M | $-425.5M | ||
| Q4 24 | $-864.6M | $1.5M | ||
| Q3 24 | $-38.2M | $-20.8M | ||
| Q2 24 | $-15.8M | $-1.4M | ||
| Q1 24 | $-110.2M | $-28.0M |
毛利率EXASMATV
| Q4 25 | 70.1% | 18.8% | ||
| Q3 25 | 68.6% | 19.3% | ||
| Q2 25 | 69.3% | 19.7% | ||
| Q1 25 | 70.8% | 15.0% | ||
| Q4 24 | 69.0% | 16.9% | ||
| Q3 24 | 69.4% | 18.8% | ||
| Q2 24 | 69.8% | 20.8% | ||
| Q1 24 | 70.0% | 16.8% |
营业利润率EXASMATV
| Q4 25 | -9.4% | 2.2% | ||
| Q3 25 | -3.0% | 3.1% | ||
| Q2 25 | -0.3% | 3.8% | ||
| Q1 25 | -13.6% | -88.8% | ||
| Q4 24 | -122.8% | 0.6% | ||
| Q3 24 | -5.6% | 1.4% | ||
| Q2 24 | -3.8% | 2.0% | ||
| Q1 24 | -16.7% | -2.8% |
净利率EXASMATV
| Q4 25 | -9.8% | 21.8% | ||
| Q3 25 | -2.3% | -0.6% | ||
| Q2 25 | -0.1% | -1.8% | ||
| Q1 25 | -14.3% | -87.8% | ||
| Q4 24 | -121.2% | 0.3% | ||
| Q3 24 | -5.4% | -4.2% | ||
| Q2 24 | -2.3% | -0.3% | ||
| Q1 24 | -17.3% | -5.6% |
每股收益（稀释后）EXASMATV
| Q4 25 | $-0.45 | $1.87 | ||
| Q3 25 | $-0.10 | $-0.06 | ||
| Q2 25 | $-0.01 | $-0.18 | ||
| Q1 25 | $-0.54 | $-7.82 | ||
| Q4 24 | $-4.69 | $0.03 | ||
| Q3 24 | $-0.21 | $-0.38 | ||
| Q2 24 | $-0.09 | $-0.03 | ||
| Q1 24 | $-0.60 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $84.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $2.4B | $498.7M |
| 总资产 | $5.9B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 2.07× |
8季度趋势，按日历期对齐
现金及短期投资EXASMATV
| Q4 25 | $964.7M | $84.2M | ||
| Q3 25 | $1.0B | $97.1M | ||
| Q2 25 | $858.4M | $95.6M | ||
| Q1 25 | $786.2M | $84.0M | ||
| Q4 24 | $1.0B | $94.3M | ||
| Q3 24 | $1.0B | $162.2M | ||
| Q2 24 | $946.8M | $133.4M | ||
| Q1 24 | $652.1M | $128.9M |
总债务EXASMATV
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
股东权益EXASMATV
| Q4 25 | $2.4B | $498.7M | ||
| Q3 25 | $2.5B | $397.4M | ||
| Q2 25 | $2.5B | $416.6M | ||
| Q1 25 | $2.4B | $428.2M | ||
| Q4 24 | $2.4B | $858.5M | ||
| Q3 24 | $3.2B | $882.3M | ||
| Q2 24 | $3.2B | $898.0M | ||
| Q1 24 | $3.1B | $906.9M |
总资产EXASMATV
| Q4 25 | $5.9B | $2.1B | ||
| Q3 25 | $5.9B | $2.0B | ||
| Q2 25 | $5.8B | $2.1B | ||
| Q1 25 | $5.7B | $2.1B | ||
| Q4 24 | $5.9B | $2.4B | ||
| Q3 24 | $6.7B | $2.6B | ||
| Q2 24 | $6.7B | $2.6B | ||
| Q1 24 | $6.4B | $2.7B |
负债/权益比EXASMATV
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.63× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 1.30× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $8.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 1.7% |
| 资本支出强度资本支出/营收 | 3.6% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.19× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $93.8M |
8季度趋势，按日历期对齐
经营现金流EXASMATV
| Q4 25 | $151.7M | $19.3M | ||
| Q3 25 | $219.9M | $72.8M | ||
| Q2 25 | $89.0M | $57.6M | ||
| Q1 25 | $30.8M | $-15.9M | ||
| Q4 24 | $47.1M | $24.1M | ||
| Q3 24 | $138.7M | $37.6M | ||
| Q2 24 | $107.1M | $46.1M | ||
| Q1 24 | $-82.3M | $-13.0M |
自由现金流EXASMATV
| Q4 25 | $120.4M | $8.0M | ||
| Q3 25 | $190.0M | $66.7M | ||
| Q2 25 | $46.7M | $48.9M | ||
| Q1 25 | $-365.0K | $-29.8M | ||
| Q4 24 | $10.7M | $2.0M | ||
| Q3 24 | $112.6M | $25.5M | ||
| Q2 24 | $71.2M | $37.4M | ||
| Q1 24 | $-120.0M | $-25.1M |
自由现金流率EXASMATV
| Q4 25 | 13.7% | 1.7% | ||
| Q3 25 | 22.3% | 13.0% | ||
| Q2 25 | 5.8% | 9.3% | ||
| Q1 25 | -0.1% | -6.1% | ||
| Q4 24 | 1.5% | 0.4% | ||
| Q3 24 | 15.9% | 5.1% | ||
| Q2 24 | 10.2% | 7.1% | ||
| Q1 24 | -18.8% | -5.0% |
资本支出强度EXASMATV
| Q4 25 | 3.6% | 2.4% | ||
| Q3 25 | 3.5% | 1.2% | ||
| Q2 25 | 5.2% | 1.7% | ||
| Q1 25 | 4.4% | 2.9% | ||
| Q4 24 | 5.1% | 4.8% | ||
| Q3 24 | 3.7% | 2.4% | ||
| Q2 24 | 5.1% | 1.7% | ||
| Q1 24 | 5.9% | 2.4% |
现金转化率EXASMATV
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 16.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
